Yesterday | MarketWatch
Teva meets estimates, led by Copaxone, generics
Teva Pharmaceutical Industries Inc. reported first-quarter net income fell 57% on Tuesday, reflecting a charge tied to an acquisition. via MarketWatch
Thursday May 8 | Fool.com
“Well, China's big -- I'll buy China.”
My Motley Fool colleagues and I recently sat down with Dr. Jeremy Siegel, noted professor of finance at the University of Pennsylvania's Wharton School, to talk investing. via Fool.com
Tuesday May 6 | Earth Times
'CNS Generic Drugs: Prospects and Opportunities to 2012' Now Available
Research and Markets has announced the addition of CNS Generic Drugs: Prospects and Opportunities to 2012 to their offering. via Earth Times
Tuesday May 6 | Earth Times
Teva quarterly net profit down on CoGenesys charge
Teva Pharmaceutical Industries Ltd , the world's largest generic drugmaker, on Tuesday reported a drop in its first-quarter net profit, weighed by a charge tied to its acquisition of CoGenesys. via Earth Times
Monday May 5 | Marine Corps Gazette
Material Handler, TEVA Pharmaceuticals
Overview : Teva Pharmaceuticals USA is the leading global generic pharmaceutical company employing 26,000 people worldwide. via Marine Corps Gazette
Wednesday Apr 30 | New Hampshire Business Review
Bentley board members stand to cash in on Teva deal
The Bentley Pharmaceutical officials recommending that stockholders sell the company to Teva Pharmaceutical Industries Limited expect to receive more than $70 million on the $360 million deal, according to a ... via New Hampshire Business Review
Monday Apr 28 | Business Wire
Public relations, press release distribution, investor relations, SEC filing
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted approval for the Company - 04/28/2008 - 03:39 PM AUSTIN, Texas-- --Fitch rates the following City of ... via Business Wire
Saturday Apr 26 | The Motley Fool
Wyeth Recovers From Its Heartburn
The only thing worse for a pharmaceutical company than generic competition is generic competition that it didn't prepare for. via The Motley Fool
Thursday Apr 24 | Forbes.com
Wyeth Needs A Good Anti-Depressant
Wyeth 's profit fell in its first quarter as it cut workers to cope with generic competition. via Forbes.com
Tuesday Apr 22 | Med Ad News
Teva Pharmaceuticals USA Responds to FDA Findings on Budeprion XL 300 mg
Apr 16, 2008 - Teva Pharmaceuticals USA issues the following statement in response to the "Review of Therapeutic Equivalence Generic Bupropion XL 300 mg and Wellbutrin XL 300 mg" released by FDA on April 16, ... via Med Ad News







